PETROS PHARMACEUTICALS INC (PTPI)

Company Profile

Petros Pharmaceuticals, Inc. engages in men's health therapeutics. The company is headquartered in New York City, New York and currently employs 24 full-time employees. The company went IPO on 2020-12-02. The firm is focused on men’s health therapeutics with a full range of commercial capabilities including sales, marketing, regulatory and medical affairs, finance, trade relations, pharmacovigilance, market access relations, manufacturing, and distribution. The company commercializes therapeutics for men's health issues, such as endothelial dysfunction, psychosexual and psychosocial ailments, hormone health, and substance-use disorders. The company also commercializes and develops Stendra, a PDE-5 inhibitor prescription medication for the treatment of erectile dysfunction (ED). The company also markets its own line of ED products in the form of vacuum erection device products through its subsidiaries, Timm Medical and PTV. In addition to ED products, it has a global license (the Hybrid License) to develop and commercialize H100, a novel and patented topical formulation candidate for the treatment of acute Peyronies disease.

Company Info

PETROS PHARMACEUTICALS INC

1185 Avenue Of The Americas, 3Rd Floor, Suite 570

New York City NEW YORK 10036

P: 19732420005

CEO: John D. Shulman

Employees: 24

Website: https://www.petrospharma.com/